Can 'Moon Shot' Lift FDA Out Of Its Silos?
This article was originally published in Scrip
Executive Summary
Even though the White House's "moon shot" initiative is focused on cancer, a key component of the program – a new multimillion-dollar FDA "virtual" center for excellence intended to expedite the development and regulatory review of new combination therapies – may be the force to lift the agency out of its silos so that drugs, devices and diagnostics intended to be used together for other types of diseases are not forced to undergo time-consuming separate assessments, said Ellen Sigal, founder and chair of the advocacy group Friends of Cancer Research (FOCR).
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.